We are developing next-generation gene editing medicines to cure rare genetic diseases
Gene editing allows to cure genetic diseases at their roots by correcting inborn genetic errors directly in patients’ cells.
Safety first. Our synergic core technologies increase the precision of genetic modifications and reduce the risks for patients. We bring gene editing to the next level of specificity, making it more suitable for applications in the clinic.
Alia Therapeutics stems from research conducted at the University of Trento (Italy) aimed at improving the safety profile and the delivery of genome editing tools. The company has been incorporated in 2018 and is currently incubated at CIBIO, the biotech department of the University of Trento.